Literature DB >> 31755000

The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility.

Jure Bedenk1, Eda Vrtačnik-Bokal2, Irma Virant-Klun2.   

Abstract

PURPOSE: In this review, the current knowledge on anti-Müllerian hormone (AMH) is presented, concerning its value in disease and IVF treatment as well as in terms of its prospective clinical use.
METHODS: AMH is becoming the most appropriate biomarker for the ovarian reserve measured predominantly for assisted reproductive treatment (ART) patients in comparison to the currently used antral follicle count (AFC). However, this is not the only way AMH measurements can be used in the clinics. Because of this, we reviewed the current literature for the use of AMH in current or prospective clinical practice.
RESULTS: We found that AMH has a high predictive value in assessing the ovarian reserve, which can lead to a better efficiency of in vitro fertilization (IVF) procedures. It has a high potential to be developed as a staple diagnostic marker of ovarian disease, especially for ovarian cancers and even as a possible treatment tool for certain cancers. It could potentially be used to prevent oocyte loss due to chemo- or radiotherapy.
CONCLUSION: AMH is an important hormone especially in women reproductive organs and is currently seen as the best biomarker for a multitude of uses in reproductive medicine. Currently, the biggest issue lies in the lack of international standardization of AMH. However, it is encouraging to see that there is interest in AMH in the form of research on its action and use in reproductive medicine.

Entities:  

Keywords:  Anti-Müllerian hormone; Assisted reproductive technology; Fertility; Hormone receptor; In vitro fertilization; Oocyte

Mesh:

Substances:

Year:  2019        PMID: 31755000      PMCID: PMC7000586          DOI: 10.1007/s10815-019-01622-7

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  102 in total

Review 1.  The role of Amh signaling in teleost fish--Multiple functions not restricted to the gonads.

Authors:  Frank Pfennig; Andrea Standke; Herwig O Gutzeit
Journal:  Gen Comp Endocrinol       Date:  2015-09-30       Impact factor: 2.822

2.  Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population.

Authors:  M McIlveen; J D Skull; W L Ledger
Journal:  Hum Reprod       Date:  2006-11-17       Impact factor: 6.918

3.  Anti-müllerian hormone levels are associated with live birth rates in ART, but the predictive ability of anti-müllerian hormone is modest.

Authors:  Sara S E Alson; Leif J Bungum; Aleksander Giwercman; Emir Henic
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2018-05-02       Impact factor: 2.435

4.  A multicentre evaluation of the Elecsys® anti-Müllerian hormone immunoassay for prediction of antral follicle count.

Authors:  Michael H Jacobs; Laura M Reuter; Valerie L Baker; LaTasha B Craig; Denny Sakkas; Eric Surrey; Kevin J Doody; Emily S Jungheim; Aykut B Bayrak; Martin Hund; Wilma D J Verhagen-Kamerbeek; Deborah Pardue; Katharina Buck; Barbara Timm
Journal:  Reprod Biomed Online       Date:  2019-01-08       Impact factor: 3.828

Review 5.  Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer.

Authors:  Richard A Anderson; W Hamish B Wallace
Journal:  Fertil Steril       Date:  2013-03-27       Impact factor: 7.329

6.  Early follicular antimüllerian hormone as an indicator of ovarian reserve.

Authors:  Cem Fiçicioglu; Tayfun Kutlu; Elif Baglam; Zeynep Bakacak
Journal:  Fertil Steril       Date:  2006-03       Impact factor: 7.329

7.  The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors--A comparative study with inhibin B.

Authors:  Anniina Färkkilä; Sanna Koskela; Saara Bryk; Henrik Alfthan; Ralf Bützow; Arto Leminen; Ulla Puistola; Juha S Tapanainen; Markku Heikinheimo; Mikko Anttonen; Leila Unkila-Kallio
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

8.  Impact of breast cancer on anti-mullerian hormone levels in young women.

Authors:  H I Su; S W Flatt; L Natarajan; A DeMichele; A Z Steiner
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

Review 9.  Polycystic ovary syndrome.

Authors:  Robert J Norman; Didier Dewailly; Richard S Legro; Theresa E Hickey
Journal:  Lancet       Date:  2007-08-25       Impact factor: 79.321

10.  Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF?

Authors:  Mohar Goswami; Dimitrios Nikolaou
Journal:  J Hum Reprod Sci       Date:  2017 Jan-Mar
View more
  10 in total

1.  Which ovarian stimulation parameters influence the number and proportion of mature oocytes retrieved in IVF cycles?

Authors:  Ankita Sethi; Neeta Singh; Garima Patel
Journal:  J Assist Reprod Genet       Date:  2021-10-08       Impact factor: 3.412

2.  Effect of folic acid supplementation on diminished ovarian reserve: study protocol of a single-centre, open-label, randomised, placebo-controlled clinical trial.

Authors:  Kaijun Liao; Yan Wang; Ling Zheng; Dongli Lu; Jiaxin Wu; Binjin Wu; Zhaochun Wu; Zhenghua Jiang
Journal:  BMJ Open       Date:  2022-07-04       Impact factor: 3.006

3.  Evaluation of Serum AMH, INHB Combined with Basic FSH on Ovarian Reserve Function after Laparoscopic Ovarian Endometriosis Cystectomy.

Authors:  Yan Tang; Yanning Li
Journal:  Front Surg       Date:  2022-05-18

Review 4.  Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care.

Authors:  Robert Sheppard Nickel; Jacqueline Y Maher; Michael H Hsieh; Meghan F Davis; Matthew M Hsieh; Lydia H Pecker
Journal:  J Clin Med       Date:  2022-04-21       Impact factor: 4.964

5.  Roles of kisspeptin in IVF/ICSI-treated infertile women and in human granulosa cells.

Authors:  Lixian Qin; Chantacha Sitticharoon; Somsin Petyim; Issarawan Keadkraichaiwat; Rungnapa Sririwichitchai; Pailin Maikeaw; Malika Churintaraphan; Chanakarn Sripong
Journal:  Exp Biol Med (Maywood)       Date:  2020-12-16

6.  Abnormalities of early folliculogenesis and serum anti-Müllerian hormone in chinese patients with polycystic ovary syndrome.

Authors:  Juan Du; Xiangyan Ruan; Fengyu Jin; Yanglu Li; Jiaojiao Cheng; Muqing Gu; Alfred Otto Mueck
Journal:  J Ovarian Res       Date:  2021-02-18       Impact factor: 4.234

7.  The Clinical Outcome of Laparoscopic Surgery for Endometriosis on Pain, Ovarian Reserve, and Cancer Antigen 125 (CA-125): A Cohort Study.

Authors:  Fereshte Sarbazi; Elham Akbari; Anita Karimi; Behnaz Nouri; S Hahla Noori Ardebili
Journal:  Int J Fertil Steril       Date:  2021-10-16

8.  Correlation between anti-Müllerian hormone, age, and number of oocytes: A retrospective study in a Brazilian in vitro fertilization center.

Authors:  Isadora Ferreira Kozlowski; Matheus Campos Carneiro; Vinicius Bonato da Rosa; Alessandro Schuffner
Journal:  JBRA Assist Reprod       Date:  2022-04-17

Review 9.  A Narrative Review of Current Understanding of the Pathophysiology of Polycystic Ovary Syndrome: Focus on Plausible Relevance of Vitamin D.

Authors:  Rajeshwari Kalyanaraman; Lubna Pal
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

10.  Development and Validation of Prediction Model for High Ovarian Response in In Vitro Fertilization-Embryo Transfer: A Longitudinal Study.

Authors:  Xinsha Tan; Honglin Xi; Jing Yang; Wenfeng Wang
Journal:  Comput Math Methods Med       Date:  2021-10-16       Impact factor: 2.238

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.